A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2017

At a glance

  • Drugs SM 04690 (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Samumed
  • Most Recent Events

    • 20 Jun 2017 According to a Samumed media release, the company expects to report the 52-week safety, signs & symptoms and potential cartilage regeneration data from this study at a future medical conference.
    • 20 Jun 2017 Status changed from active, no longer recruiting to completed, according to a Samumed media release.
    • 17 Jun 2017 Week 26 interim analysis results evaluating safety and efficacy of SM04690 IA injection presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top